These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32792087)

  • 21. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
    Goldstein LB; Amarenco P; Szarek M; Callahan A; Hennerici M; Sillesen H; Zivin JA; Welch KM;
    Neurology; 2008 Jun; 70(24 Pt 2):2364-70. PubMed ID: 18077795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
    Amarenco P; Benavente O; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; Gilbert S; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2009 Apr; 40(4):1405-9. PubMed ID: 19228842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Mascitelli L; Pezzetta F; Goldstein MR; Chaturvedi S
    Neurology; 2009 Jul; 73(3):249; author reply 249-50. PubMed ID: 19620618
    [No Abstract]   [Full Text] [Related]  

  • 26. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Amarenco P; Goldstein LB; Messig M; O'Neill BJ; Callahan A; Sillesen H; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2009 Jul; 40(7):2486-92. PubMed ID: 19461031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy.
    Wiviott SD; Cannon CP
    Curr Opin Lipidol; 2006 Dec; 17(6):626-30. PubMed ID: 17095906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracerebral Hemorrhage in SPARCL: What Was the Relationship to LDL-C?
    Spence JD
    J Am Coll Cardiol; 2020 Aug; 76(7):885-886. PubMed ID: 32792086
    [No Abstract]   [Full Text] [Related]  

  • 29. High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
    Khan M; Kamran KA
    J Pak Med Assoc; 2010 Jun; 60(6):505-6. PubMed ID: 20527658
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
    Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid assessment and treatment patterns in hospitalized TIA and ischemic stroke patients.
    Ovbiagele B; Hills NK; Saver JL; Johnston SC;
    J Hosp Med; 2006 Jul; 1(4):214-20. PubMed ID: 17219502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
    Arrospide A; Mar J; Vivancos-Mora J; Rejas-Gutiérrez J; Caro J
    Rev Neurol; 2010 Jul; 51(1):1-11. PubMed ID: 20568062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke).
    Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
    Stroke; 2018 Apr; 49(4):865-871. PubMed ID: 29511130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
    Kitagawa K; Hosomi N; Nagai Y; Kagimura T; Ohtsuki T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Nakamura M; Matsumoto M;
    J Atheroscler Thromb; 2019 May; 26(5):432-441. PubMed ID: 30318492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency and determinants of lipid testing in ischemic stroke and transient ischemic attack: findings from get with the guidelines-stroke.
    Smith EE; Pan W; Olson D; Reeves MJ; Ovbiagele B; Peterson ED; Fonarow GC; Schwamm LH
    Stroke; 2010 Feb; 41(2):232-8. PubMed ID: 20035071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
    Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJ; Grundy SM
    J Am Coll Cardiol; 2006 Nov; 48(9):1793-9. PubMed ID: 17084252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
    Marchione P; Vento C; Morreale M; Izzo C; Maugeri A; Manuppella F; Romeo T; Giacomini P
    J Stroke Cerebrovasc Dis; 2015 Jan; 24(1):138-43. PubMed ID: 25440329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.
    Zanchetti A; Liu L; Mancia G; Parati G; Grassi G; Stramba-Badiale M; Silani V; Bilo G; Corrao G; Zambon A; Scotti L; Zhang X; Wang H; Zhang Y; Zhang X; Guan TR; Berge E; Redon J; Narkiewicz K; Dominiczak A; Nilsson P; Viigimaa M; Laurent S; Agabiti-Rosei E; Wu Z; Zhu D; Rodicio JL; Ruilope LM; Martell-Claros N; Pinto F; Schmieder RE; Burnier M; Banach M; Cifkova R; Farsang C; Konradi A; Lazareva I; Sirenko Y; Dorobantu M; Postadzhiyan A; Accetto R; Jelakovic B; Lovic D; Manolis AJ; Stylianou P; Erdine S; Dicker D; Wei G; Xu C; Xie H; Coca A; O'Brien J; Ford G
    J Hypertens; 2014 Sep; 32(9):1888-97. PubMed ID: 24979303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
    Castilla-Guerra L; Fernandez-Moreno MDC; Leon-Jimenez D; Rico-Corral MA
    Curr Treat Options Neurol; 2019 Apr; 21(5):22. PubMed ID: 30957208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.